ursodeoxycholic acid has been researched along with Lung Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Fujioka, M; Genda, T; Hara, M; Iwakami, N; Iwakami, SI; Kurokawa, K; Miyashita, Y; Sasaki, S; Takahashi, K | 1 |
| Brackett, LM; Reddy, CA; Schneider, BJ; Tai, AW | 1 |
| Lafferty, H; MacLaren, V; Talbot, S | 1 |
| Descourt, R; Fouchard, M; Jantzem, H; Poureau, PG; Quere, G; Robinet, G | 1 |
| Akiyama, Y; Handa, S; Kobayashi, K; Kudo, K; Kudoh, S; Soma, T; Takeda, Y | 2 |
| Hojo, M; Izumi, S; Kamimura, M; Kobayashi, K; Kudo, K; Naka, G; Takeda, Y; Tsuduki, E | 1 |
2 trial(s) available for ursodeoxycholic acid and Lung Neoplasms
| Article | Year |
|---|---|
A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antacids; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cholagogues and Choleretics; Cisplatin; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Maximum Tolerated Dose; Middle Aged; Sodium Bicarbonate; Survival Analysis; Ursodeoxycholic Acid | 2005 |
Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
Topics: Adult; Aged; Antacids; Antineoplastic Agents, Phytogenic; Bone Marrow; Buffers; Camptothecin; Case-Control Studies; Defecation; Diarrhea; Digestive System; Female; Humans; Hydrogen-Ion Concentration; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Middle Aged; Risk Factors; Sodium Bicarbonate; Ursodeoxycholic Acid | 2001 |
5 other study(ies) available for ursodeoxycholic acid and Lung Neoplasms
| Article | Year |
|---|---|
Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Cholestasis; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Bile Duct Diseases; Cholagogues and Choleretics; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunotherapy; Lung Neoplasms; Middle Aged; Nivolumab; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
Sclerosing cholangitis in a patient treated with nivolumab.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cholangitis, Sclerosing; Humans; Lung Neoplasms; Male; Nivolumab; Ursodeoxycholic Acid | 2021 |
Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cholagogues and Choleretics; Cholangitis; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
[A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation].
Topics: Administration, Oral; Antacids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Defecation; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Middle Aged; Sodium Bicarbonate; Ursodeoxycholic Acid | 2002 |